These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 30604390)
1. Monoclonal Antibodies for Multiple Sclerosis: An Update. Graf J; Aktas O; Rejdak K; Hartung HP BioDrugs; 2019 Feb; 33(1):61-78. PubMed ID: 30604390 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of multiple sclerosis. Di Pauli F; Berger T; Reindl M Curr Med Chem; 2009; 16(36):4858-68. PubMed ID: 19929782 [TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibodies for the treatment of multiple sclerosis]. Sánchez-Seco VG; Casanova Peño I; Arroyo González R Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies in treatment of multiple sclerosis. Rommer PS; Dudesek A; Stüve O; Zettl UK Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305 [TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
7. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Buttmann M Expert Rev Neurother; 2010 May; 10(5):791-809. PubMed ID: 20420497 [TBL] [Abstract][Full Text] [Related]
8. Established and novel disease-modifying treatments in multiple sclerosis. Cross AH; Naismith RT J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048 [TBL] [Abstract][Full Text] [Related]
9. A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis. Sabahi Z; Daei Sorkhabi A; Sarkesh A; Naseri A; Asghar-Rezaei N; Talebi M Int Immunopharmacol; 2023 Jul; 120():110266. PubMed ID: 37209514 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. Xu X; Chi S; Wang Q; Li C; Xu B; Zhang J; Chen X Mult Scler Relat Disord; 2018 Oct; 25():322-328. PubMed ID: 30195200 [TBL] [Abstract][Full Text] [Related]
11. Safety profile of Tysabri: international risk management plan. Iaffaldano P; D'Onghia M; Trojano M Neurol Sci; 2009 Oct; 30 Suppl 2():S159-62. PubMed ID: 19882366 [TBL] [Abstract][Full Text] [Related]
12. Novel monoclonal antibodies for therapy of multiple sclerosis. Knier B; Hemmer B; Korn T Expert Opin Biol Ther; 2014 Apr; 14(4):503-13. PubMed ID: 24579720 [TBL] [Abstract][Full Text] [Related]
13. Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies. Singer BA Semin Neurol; 2016 Apr; 36(2):140-7. PubMed ID: 27116720 [TBL] [Abstract][Full Text] [Related]
14. Novel Agents for Relapsing Forms of Multiple Sclerosis. Straus Farber R; Harel A; Lublin F Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285 [TBL] [Abstract][Full Text] [Related]
15. Efficiency of antibody therapy in demyelinating diseases. Akaishi T; Nakashima I Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968 [TBL] [Abstract][Full Text] [Related]
16. Treating multiple sclerosis with monoclonal antibodies. Buttmann M; Rieckmann P Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973 [TBL] [Abstract][Full Text] [Related]